ARCT stock forecast
Our latest prediction for Arcturus Therapeutics Holdings, Inc.'s stock price was made on the Dec. 3, 2019 when the stock price was at 9.60$.
In the short term (2weeks), ARCT's stock price should underperform the market by -8.22%. During that period the price should oscillate between -11.86% and +10.08%.
In the medium term (3months), ARCT's stock price should underperform the market by -18.07%. During that period the price should oscillate between -40.63% and +21.44%.Get email alerts
About Arcturus Therapeutics Holdings, Inc.
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
At the moment the company generates 25M USD in revenues.
On its last earning announcement, the company reported a loss of -1.27$ per share.
The book value per share is 0.48$
Three months stock forecastDec. 3, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|